NovaTears (perfluorohexyloctane) / Novaliq, Bausch Health, AFT Pharma 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


12»
  • ||||||||||  NovaTears (perfluorohexyloctane) / Novaliq, Bausch Health, AFT Pharma
    Preclinical, Journal:  In Vitro and In Vivo Visualization of Perfluorohexyloctane, an Eye Drop for Dry Eye Disease, Using Infrared Emissivity. (Pubmed Central) -  Feb 4, 2025   
    PFHO quickly spread to form a layer over the surface of saline or meibum in vitro and was detected on the ocular surface in vivo for ?5 hours after topical administration. This supports findings that PFHO forms a long-lasting barrier to evaporation at the air-liquid interface of the tear film and thus reduces signs and symptoms of DED.
  • ||||||||||  NovaTears (perfluorohexyloctane) / Novaliq, Bausch Health, AFT Pharma
    Trial completion:  Effects of NOV03 on the Tear Film (clinicaltrials.gov) -  Mar 12, 2024   
    P4,  N=27, Completed, 
    PFHO was safe and well tolerated and maintained efficacy for improving signs and symptoms of DED in this year-long study of patients with DED associated with Meibomian gland dysfunction. Not yet recruiting --> Completed
  • ||||||||||  NovaTears (perfluorohexyloctane) / Novaliq, Bausch Health, AFT Pharma
    Early Adoption and Utilization of Perfluorohexyloctane for Treatment of Dry Eye Disease () -  Mar 8, 2024 - Abstract #ISPOR2024ISPOR_239;    
    Early adopters of PHO were slightly younger and had a higher proportion of patients with a DED diagnosis compared to other agents. PHO tended to have more treatment-experienced patients in the 12 months prior to initiation, potentially highlighting a subgroup of the patient population who were waiting for a new treatment option for evaporative DED in addition to inflammation.
  • ||||||||||  NovaTears (perfluorohexyloctane) / Novaliq, Bausch Health, AFT Pharma
    Journal:  Influence of perfluorohexyloctane (Evotears (Pubmed Central) -  Dec 17, 2023   
    F6H8 may be a suitable treatment option to improve the accuracy of refractive assessment, although it increases HOA. Further studies are needed to confirm the effect on HOA and the repeatability of measurement.
  • ||||||||||  NovaTears (perfluorohexyloctane) / Novaliq, Bausch Health, AFT Pharma
    Journal:  Oxygen-Carrying Capacity of Perfluorohexyloctane, a Novel Eye Drop for Dry Eye Disease. (Pubmed Central) -  Jul 3, 2023   
    The current study confirms that PFHO contains a significant amount of oxygen, more so than that calculated for tears in equilibrium with air. Once instilled on the eye, PFHO is not expected to be a barrier to the oxygen necessary for a healthy cornea and may in fact deliver nonreactive oxygen to the cornea to facilitate healing in patients with dry eye disease.
  • ||||||||||  NovaTears (perfluorohexyloctane) / Novaliq, Bausch Health, AFT Pharma
    Preclinical, Journal:  In Vitro Inhibition of Evaporation with Perfluorohexyloctane, an Eye Drop for Dry Eye Disease. (Pubmed Central) -  Jun 30, 2023   
    PFHO significantly inhibited the R of saline in this in vitro model. The data support the idea that PHFO may form an antievaporative layer on the tear film surface and may be a functional substitute for the native tear-film lipid layer in patients with dry eye disease.
  • ||||||||||  NovaTears (perfluorohexyloctane) / Novaliq, Bausch Health, AFT Pharma
    Phase classification, Trial initiation date:  Effects of NOV03 on the Tear Film (clinicaltrials.gov) -  Apr 26, 2023   
    P4,  N=30, Not yet recruiting, 
    The data support the idea that PHFO may form an antievaporative layer on the tear film surface and may be a functional substitute for the native tear-film lipid layer in patients with dry eye disease. Phase classification: P2 --> P4 | Initiation date: Mar 2023 --> Nov 2023
  • ||||||||||  NovaTears (perfluorohexyloctane) / Novaliq, Bausch Health, AFT Pharma
    New P2 trial, New P4 trial:  Effects of NOV03 on the Tear Film (clinicaltrials.gov) -  Feb 13, 2023   
    P2,  N=30, Not yet recruiting, 
  • ||||||||||  NovaTears (perfluorohexyloctane) / Novaliq, Bausch Health, AFT Pharma
    Trial completion:  Tear Lipid Layer Thickness Assessments With Perfluorohexyloctane Eye Drops (clinicaltrials.gov) -  Feb 8, 2023   
    P=N/A,  N=20, Completed, 
    NOV03 was well tolerated, with an adverse event profile similar to that of saline. Active, not recruiting --> Completed
  • ||||||||||  NovaTears (perfluorohexyloctane) / Novaliq, Bausch Health, AFT Pharma
    Enrollment closed, Trial completion date:  Tear Lipid Layer Thickness Assessments With Perfluorohexyloctane Eye Drops (clinicaltrials.gov) -  Oct 17, 2022   
    P=N/A,  N=20, Active, not recruiting, 
    NOV03 appeared well tolerated in this population. Not yet recruiting --> Active, not recruiting | Trial completion date: Jul 2022 --> Nov 2022
  • ||||||||||  NovaTears (perfluorohexyloctane) / Novaliq, Bausch Health
    Spectroscopic study of perfluorohexyloctane – human meibum interactions (A0250) -  Apr 29, 2022 - Abstract #ARVO2022ARVO_3369;    
    However, PFHO did not change the lipid order in meibum from a healthy volunteer. We speculate that PFHO could form a protective layer on the tear film surface that enhances tear film spreading as well as decreasing the rate of evaporation.
  • ||||||||||  NovaTears (perfluorohexyloctane) / Novaliq, Bausch Health
    Clinical, Journal:  Sight-threatening Complication of Cicatricial Ectropion in a Patient with Lamellar Ichthyosis - Case Report. (Pubmed Central) -  Jun 22, 2021   
    The patient was referred to a dermatologist and was started on systemic retinoid acitretin at a dose of 0.5 mg/kg per day...Infection in the cornea can rapidly progress to corneal melting in patients with severe cicatricial ectropion. A good patient outcome depends on the interdisciplinary approach to patient management by the ophthalmologist, dermatologist, and plastic surgeon.
  • ||||||||||  Zaltrap (ziv-aflibercept IV) / Sanofi, Regeneron
    Journal:  VEGF Trap Suspended in the Semifluorinated Alkane F6H8 Inhibits Inflammatory Corneal Hem- and Lymphangiogenesis. (Pubmed Central) -  Nov 1, 2020   
    The purpose of this study was to test the effect of vascular endothelial growth factor (VEGF) Trap suspended in the SFA perfluorohexyloctane (Trap/F6H8) on corneal neovascularization...Our findings might open new treatment avenues for local anti-angiogenic therapy at the cornea, as F6H8 is already approved for the usage at the ocular surface. With this study we show for the first time that SFAs can serve as carriers for anti-angiogenic drugs at the ocular surface.
  • ||||||||||  perfluorohexyloctane (NOV03) / Novaliq, Bausch Health
    Review, Journal:  Tamponade in surgery for retinal detachment associated with proliferative vitreoretinopathy. (Pubmed Central) -  Sep 5, 2020   
    The use of either CF or standard silicone oil appears reasonable for most patients with RD associated with PVR. Heavy silicone oil, which is not available for routine clinical use in the USA, may not demonstrate evidence of superiority over standard silicone oil.
  • ||||||||||  perfluorohexyloctane (NOV03) / Novaliq, Bausch Health
    Journal:  A Review on Evidence-Based Treatments for Meibomian Gland Dysfunction. (Pubmed Central) -  Sep 4, 2020   
    All eight forms of treatments, including self-applied eyelid warming, thermal pulsation, IPL, MG probing, antibiotics, lipid-containing eye drops, and perfluorohexyloctane, were effective against MGD, although with varying extent of clinical improvements. A better understanding on the mechanisms of actions may guide physicians to make better treatment decisions targeting the root causes.
  • ||||||||||  perfluorohexyloctane (NOV03) / Novaliq, Bausch Health
    Journal:  From nano-seggregation to mesophases: probing the liquid structure of perfluoroalkylalkanes with Xe NMR spectroscopy. (Pubmed Central) -  Jun 27, 2020   
    It is important to stress that nano-segregation is this case observed in liquids interacting exclusively through dispersion forces, unlike most common examples of segregation which are determined by hydrogen bonding and polarity. Given the simple molecular structure and interactions of the studied PFAA, we believe that the present results can have a general impact in understanding the early mechanisms of segregation, phase separation and self-assembly.